Ilmarinen Mutual Pension Insurance Co cut its holdings in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 27.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 17,400 shares of the biotechnology company’s stock after selling 6,600 shares during the period. Ilmarinen Mutual Pension Insurance Co’s holdings in Biogen were worth $3,062,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in Biogen by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 17,447,092 shares of the biotechnology company’s stock worth $3,070,514,000 after acquiring an additional 157,857 shares during the period. Geode Capital Management LLC grew its holdings in Biogen by 3.2% during the 4th quarter. Geode Capital Management LLC now owns 4,199,399 shares of the biotechnology company’s stock worth $736,435,000 after acquiring an additional 130,618 shares during the period. Invesco Ltd. grew its holdings in Biogen by 4.2% during the 3rd quarter. Invesco Ltd. now owns 2,418,127 shares of the biotechnology company’s stock worth $338,731,000 after acquiring an additional 98,001 shares during the period. AQR Capital Management LLC grew its position in shares of Biogen by 30.7% during the 3rd quarter. AQR Capital Management LLC now owns 1,783,581 shares of the biotechnology company’s stock worth $248,809,000 after buying an additional 418,776 shares during the period. Finally, Legal & General Group Plc grew its position in shares of Biogen by 10.1% during the 3rd quarter. Legal & General Group Plc now owns 1,593,399 shares of the biotechnology company’s stock worth $223,203,000 after buying an additional 146,583 shares during the period. Institutional investors and hedge funds own 87.93% of the company’s stock.
Wall Street Analysts Forecast Growth
Several equities analysts have recently issued reports on BIIB shares. Mizuho boosted their target price on Biogen from $207.00 to $236.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 10th. Wells Fargo & Company boosted their target price on Biogen from $190.00 to $200.00 and gave the stock an “equal weight” rating in a research report on Sunday, February 8th. Guggenheim boosted their target price on Biogen from $246.00 to $260.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. HC Wainwright reissued a “buy” rating on shares of Biogen in a report on Thursday, May 14th. Finally, Wall Street Zen raised shares of Biogen from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $215.81.
Biogen Price Performance
Shares of BIIB opened at $196.00 on Friday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.41 and a current ratio of 3.06. The stock has a 50 day simple moving average of $186.66 and a 200 day simple moving average of $182.21. Biogen Inc. has a 52-week low of $121.05 and a 52-week high of $205.97. The firm has a market capitalization of $28.94 billion, a PE ratio of 21.03, a P/E/G ratio of 1.73 and a beta of 0.19.
Biogen (NASDAQ:BIIB – Get Free Report) last issued its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The business had revenue of $2.48 billion during the quarter, compared to analyst estimates of $2.29 billion. During the same period in the previous year, the firm earned $3.02 EPS. Biogen’s quarterly revenue was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Sell-side analysts predict that Biogen Inc. will post 14.18 EPS for the current fiscal year.
Biogen Profile
Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.
The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.
Featured Stories
- Five stocks we like better than Biogen
- Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys
- Salesforce Stock Finds Support as AI Momentum Builds
- Dollar Tree Keeps Winning After Family Dollar Divorce
- Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet
Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB – Free Report).
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.
